Two selected reports describe early development and a phase 2 trial of an antibody–peptide conjugate combining GIP-receptor antagonism with GLP-1-receptor agonism. Animal experiments and human trial results are separate evidence.12
Bottom line from this bounded source set
The phase 2 trial reported greater weight reduction than placebo over 52 weeks in participants with obesity, with or without type 2 diabetes. Gastrointestinal events were common. These results do not establish long-term clinical outcomes or an approved indication.12
Reviewed study record
Early translational and human program
Design
The publication combines preclinical experiments with an early randomized clinical trial.1
Population
The human trial enrolled people with obesity; animal findings in the same report are not human outcomes.1
Outcomes reported
The authors reported weight reductions in the early human program alongside pharmacologic and preclinical findings.1
Limitations
The abstract does not support a complete participant-flow or harms appraisal. Early exploratory findings cannot establish durable clinical benefit, and the conjugate is not interchangeable with other peptides.1
Reviewed study record
Phase 2 obesity trial
Design
Randomized, placebo-controlled 52-week trial with multiple active groups; NCT05669599.2
Population
592 participants: 465 with obesity without diabetes and 127 with obesity and type 2 diabetes.2
Outcomes reported
In the intention-to-treat analysis, weight changes ranged from −12.3% to −16.2% versus −2.5% without diabetes, and −8.4% to −12.3% versus −1.7% with diabetes. Gastrointestinal events were common.2
Limitations
Multiple groups and two populations should not be pooled into a single effect. Weight is not a direct measure of cardiovascular outcomes, and longer-term safety remains unresolved.2
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1038/s42255-023-00966-w. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1056/nejmoa2504214. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗